我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
10
3 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
进行中（未招募）
1
10.0%
已完成
5
50.0%
尚未招募
2
20.0%
招募中
暂无批准数据
- Kardium Inc. received Health Canada approval to sell its Globe Pulsed Field System, a pulsed field ablation device for treating atrial fibrillation, following FDA approval in August 2025. - The device uses 122 individually controlled electrodes for high-density mapping and ablation, with a global study showing 77.8% of 183 patients free of atrial fibrillation at 12 months. - The Vancouver-based company received a $31.25-million federal funding boost to expand clean room manufacturing capacity from 10,000 to 25,000 square feet. - Atrial fibrillation affects nearly 60 million people worldwide, and Kardium plans to go public as early as the second half of 2027.
